Adderall Shortage 2026: Status, Causes & What to Do

Yes, the Adderall shortage is still active in 2026. The FDA's shortage notice, first posted in October 2022, remains live, and ASHP lists both immediate-release and extended-release amphetamine mixed salts in active shortage. DEA quota increases in late 2025 and early 2026 are improving supply, but availability still varies by strength and pharmacy [1][2][3].

The Adderall shortage has now stretched past the three-and-a-half-year mark. What began in October 2022 as a manufacturing delay at Teva Pharmaceuticals has hardened into one of the longest-running prescription drug shortages in recent US history, drawing in other stimulant medications, multiple manufacturers, and two federal agencies [1][4].

This guide covers where the shortage stands in 2026, the supply-and-demand mechanics behind it, what the DEA's recent quota changes actually mean for pharmacy shelves, and the practical steps patients can take with their prescriber and pharmacist while supply remains patchy.

Is the Adderall Shortage Still Going On in 2026?

Yes, the Adderall shortage is still active in 2026. The FDA's shortage notice for amphetamine mixed salts, first posted in October 2022, remains live, and ASHP continues to list both immediate-release tablets and extended-release capsules in active shortage, with availability varying by strength and pharmacy.

That headline status hides a lot of local variation. Some pharmacies fill prescriptions without trouble. Others have specific strengths on back order for weeks. According to ASHP manufacturer reports compiled in early 2026, brand Adderall IR remains available from Teva, while several generic strengths sit on intermittent back order, with the 20 mg generic IR tablet listed with no estimated release date. Multiple XR capsule strengths are also on back order, attributed mainly to active ingredient delays and increased demand [2][4].

The supplier base has thinned, too. Mylan and Zydus discontinued their generic IR tablets, and Par, Prasco, Sandoz, and Sun Pharma discontinued XR capsules, concentrating supply among the manufacturers that remain, including Teva, Camber, Epic Pharma, Granules, Lannett, and Sunrise [2][4].

Why Is There an Adderall Shortage?

The Adderall shortage has no single cause. A surge in ADHD diagnoses and prescription fills collided with manufacturing delays at major producers inside a DEA quota system that caps how much amphetamine can be made each year, creating a supply chain with almost no buffer when demand grows faster than production can legally follow.

Demand grew faster than supply could legally follow

ADHD diagnoses have risen across every age group. A CDC report found that stimulant prescription fills jumped sharply during the pandemic years, increasing by more than 10% between 2020 and 2021 among women aged 15 to 44 and men aged 25 to 44, a period when telehealth rules for prescribing were temporarily loosened [5]. By October 2024, the CDC estimated that 15.5 million US adults had an ADHD diagnosis, and 71.5% of adults taking stimulant medication reported difficulty getting their prescription filled in the previous year [6].

The growth has not slowed. DEA figures published with the 2026 quota proposal show domestic medical use of Schedule II stimulants rose an average of 6.74% in 2024 compared with 2023, with projected growth of 8.94% for 2026 [7].

Manufacturing problems and a shrinking producer base

The shortage started with production delays at Teva, the largest producer of both brand and generic Adderall, in late 2022 [1][4]. Since then, several manufacturers have cited shortages of active pharmaceutical ingredient (API) as the constraint on their output. Others exited entirely. Each discontinuation pushes demand onto the remaining producers and makes the whole supply chain more fragile: when the biggest producer stumbles, there is nowhere for the demand to go [2][4].

The DEA quota system limits how much can be made

Adderall contains amphetamine, a Schedule II controlled substance. The DEA sets an annual aggregate production quota (APQ) that caps the total amount manufacturers can produce, and the quota system is structurally backward-looking, built on historical dispensing data that lags behind real-time demand growth [4][7]. Manufacturers must request allocations, and pharmacies must order through wholesalers who may not fill orders completely. When demand jumps faster than the quota cycle can react, the gap shows up at the pharmacy counter.

What the DEA and FDA Are Doing About It

The DEA took two significant quota actions between late 2025 and early 2026. In October 2025 it raised the d-amphetamine production quota by roughly 25%, and in January 2026 it set a final 2026 quota for the amphetamine in Adderall at 24.2 million grams, about 14% above the originally proposed level.

October 2025: a 25% quota increase. Effective October 2, 2025, the DEA raised the aggregate production quota for d-amphetamine from 21.2 million grams to about 26.45 million grams (an increase of roughly 24.8%), and raised the methylphenidate quota at the same time [8].

January 2026: higher final quotas for 2026. On January 5, 2026, the DEA published its final order establishing the 2026 aggregate production quotas. The quota for d,l-amphetamine, the racemic amphetamine used in Adderall, was set at 24,234,443 grams, roughly 14% above the originally proposed level. Lisdexamfetamine (the active ingredient in Vyvanse) was increased to 51,290,743 grams [9]. The DEA stated publicly that the action was intended to help ensure patients can access needed medications [10].

The proposed rule behind those numbers, published in November 2025, drew more than 5,000 public comments, mostly from patients and clinicians describing missed refills, forced medication switches, and the downstream effects of disrupted access [7].

Higher quotas help, but they are not an instant fix. Manufacturers are not required to produce up to their allocation, and production lead times, API sourcing, quality assurance, and distribution each add months between a quota increase and stock on a pharmacy shelf [7]. The FDA's role, meanwhile, is monitoring and coordination: it tracks supply through its drug shortage database, works with manufacturers on timelines, and publishes availability updates [3].

Which ADHD Medications Are Affected?

The shortage spread well beyond Adderall itself as prescribers switched patients to whatever was available. As of early 2026, generic amphetamine mixed salts in both immediate-release and extended-release forms remain in active shortage, while brand Adderall IR, brand Vyvanse, and non-stimulant atomoxetine are all reported as available.

Compiled from FDA Drug Shortage Database and ASHP shortage listings as reported in early 2026. Availability changes quickly and varies by region; always check the FDA database for the current status.

A pattern worth noticing: generics are hit harder than brands. Generic versions are cheaper, so demand for them is higher, and insurance plans often cover only the generic, which means a patient can face an out-of-pocket dilemma even when the brand version is sitting in stock [4][11].

How the Shortage Affects Patients

The day-to-day burden of the shortage falls on patients in ways the supply statistics don't capture.

• 30-day refill cycles with no buffer. Schedule II rules generally limit dispensing to a 30-day supply, with no 90-day option and no paying cash for extra. Every month restarts the search [4].
• Prescriptions don't transfer. If your pharmacy is out of stock, the prescription typically can't be moved to another pharmacy; the prescriber has to issue a new one to the new location, adding calls and delay each time [4].
• Pharmacy hunting feeds the chaos. Patients calling pharmacy after pharmacy creates shifting, unpredictable demand that makes it even harder for pharmacies to stock sensibly [4].
• Insurance friction. When the covered generic is unavailable, the brand may not be reimbursed, leaving patients choosing between paying full price and going without [4].
• Treatment disruption has real costs. In the CDC's 2024 data, nearly three-quarters of adults on stimulant medication reported difficulty filling a prescription [6]. Clinicians interviewed about the shortage stress that untreated ADHD carries elevated risks of accidents and worse health outcomes, which is why continuity matters [4].

What Patients Can Do During the Adderall Shortage

None of this is within a patient's power to fix, but there are practical moves that consistently help. Every medication decision below runs through your prescriber; the rest is logistics.

Start with your prescriber

• Tell them early. If a refill fails, contact your prescriber promptly rather than waiting for the next appointment. Gaps are easier to manage before they start.
• Ask about dose flexibility. Sometimes a different strength of the same medication is in stock (for example, two lower-strength tablets in place of one higher-strength one). Only a prescriber can rewrite the prescription that way [2].
• Ask about formulation and medication options. Prescribers are routinely navigating this now. Alternatives they may consider include a different stimulant (such as lisdexamfetamine or methylphenidate, where available) or non-stimulant options such as atomoxetine, viloxazine, or guanfacine ER, which are FDA-approved for ADHD and are not subject to DEA production quotas [2][11]. Which option fits is an individual clinical decision.

Work the pharmacy logistics

• Call before sending the prescription. Ask whether your exact medication and strength is in stock before your prescriber transmits it, so the prescription lands where the stock is.
• Try independent pharmacies. Smaller independents often source from different wholesalers than the big chains and may have stock when chains don't [2].
• Time refills early in the cycle. Pharmacies tend to receive deliveries early in the month; asking about refill timing can put your request ahead of the rush [2].
• Use electronic prescribing to your advantage. E-prescriptions can be redirected to a new pharmacy faster than paper, so keep your prescriber's office in the loop on which location to send to [2].

Stay informed

Check the FDA Drug Shortage Database by ingredient name before each refill, and the ASHP detail pages for estimated release dates by manufacturer [2][3]. For a wider primer on how stimulant medications work and how they differ, our guide to study drugs, how they work, and their risks is a useful companion read.

Risks to Avoid While Supply Is Tight

In June 2024, the CDC issued a formal health advisory warning that disrupted access to prescription stimulants could increase risks of injury and overdose, specifically because patients whose access is interrupted may look for medication outside the regulated healthcare system [12].

• Never buy stimulant medication from unverified online sellers or social media. Counterfeit pills made to look like prescription stimulants can contain fentanyl or other dangerous substances, and there is no way to tell by sight [12].
• Don't ration or stop without telling your prescriber. Skipping or splitting doses to stretch a supply changes how the medication works and hides the problem from the person who can actually fix it. If a gap is unavoidable, your prescriber can plan for it.
• Don't borrow medication. Someone else's prescription is a different strength, formulation, and risk profile, as well as being illegal to share.

When Will the Adderall Shortage End?

There is no confirmed end date. The DEA's 2025 and 2026 quota increases are meaningful, but their effect takes months to reach pharmacy shelves as manufacturers ramp up production, source API, and move product through distribution [7][8][9].

History offers a sobering benchmark. A 2025 analysis in the Journal of Pediatric Pharmacology and Therapeutics of drug shortage data from 2001 to 2023 found that amphetamine salts went through 10 separate shortage events in that period, with resolved shortages lasting 20.7 months on average. The current shortage has already run well past that average [13].

Reasons for cautious optimism: the DEA has shown willingness to adjust quotas in response to shortage data, more than 5,000 public comments on the 2026 quotas signal sustained policy attention, and remaining manufacturers are expanding capacity [7][9]. Reasons for caution: the quota system still relies on backward-looking data, demand is still projected to grow through 2026, and the producer base keeps narrowing [7]. Independent analysts' estimates for consistent nationwide supply generally point to late 2026 or 2027 [14].

Supporting Everyday Focus While You Navigate the Shortage

To be clear before anything else: decisions about ADHD medication belong with you and your prescriber, and nothing in this section is an input to that decision. No supplement is a replacement for any prescription medication.

What this section covers is the separate, everyday question of the foundations your focus rests on, which matter for everyone and become more noticeable when routines are disrupted:

• Sleep regularity. A consistent sleep and wake window does more for next-day concentration than almost any other single habit.
• Movement. Even short bouts of exercise measurably sharpen attention for the hours that follow.
• External structure. Timers, written task lists, body doubling, and single-tasking reduce the load on working memory.
• Steady fuel. Regular meals with protein, and consistent hydration, smooth out the energy dips that scatter attention.

Nutrition is the piece many people then ask about. Brainzyme® FOCUS PRO™ is a plant-powered food supplement formulated for everyday focus and a motivated mood, combining natural plant extracts with choline, B vitamins, and minerals that support normal mental performance and help reduce tiredness and fatigue. It is vegan, GMP-certified, and available without a prescription. As a food supplement, it is not intended to diagnose, treat, cure, or prevent any condition. For the research picture on what nutrition can and cannot do in this space, our evidence review on what the research says about natural focus support is a straightforward place to start, and you can browse the full focus supplement range to compare formulas.

The US Adderall Shortage in Numbers: Verified Federal Data

The figures below are drawn directly from US federal sources — the FDA Drug Shortages database, DEA aggregate production quota orders in the Federal Register, and CDC surveillance reports — plus one peer-reviewed analysis of historical shortage durations. Each row links to the primary document. Numbers are reported neutrally for reference; always check the live FDA database for current status, because availability changes by strength, region, and pharmacy.

Finding	Figure	Source
Date the FDA added amphetamine mixed salts (Adderall, immediate-release) to its drug shortage database	October 12, 2022 — still listed as a current shortage	FDA, “FDA Announces Shortage of Adderall” [1]; FDA Drug Shortages database [2]
DEA in-year increase to the 2025 d-amphetamine (for sale) aggregate production quota, effective October 2, 2025 — d-amphetamine "for sale" is a distinct DEA quota class from the d,l-amphetamine that is Adderall's active ingredient, though both feed mixed amphetamine-salt manufacturing	21,200,000 → 26,450,000 grams (an increase of about 24.8%)	DEA final order, Federal Register, Oct 2, 2025 [3]
DEA established 2026 aggregate production quota for d,l-amphetamine (the racemic amphetamine in Adderall), final order Jan 5, 2026	24,234,443 grams	DEA final order, Federal Register / govinfo.gov, Jan 5, 2026 [4]
DEA established 2026 aggregate production quota for lisdexamfetamine (the active ingredient in Vyvanse)	51,290,743 grams	DEA final order, Federal Register / govinfo.gov, Jan 5, 2026 [4]
US adults with a current ADHD diagnosis (self-reported), and the share of adults on stimulant medication who reported difficulty filling a prescription because it was unavailable	An estimated 15.5 million adults (6.0%); 71.5% reported difficulty filling their prescription	CDC, MMWR Vol. 73, No. 40 (survey fielded Oct–Nov 2023; published Oct 10, 2024) [5]
Average duration of resolved amphetamine-derivative drug shortages, 2001–2023 (across 26 shortage events identified)	20.7 months (range 1.3–61.6 months)	J Pediatr Pharmacol Ther (2025) shortage-data analysis [6]

Methodology / sources: All figures were taken directly from the primary documents cited and verified against the original text on June 19, 2026. Aggregate production quotas (APQ) are DEA manufacturing limits, not a direct measure of pharmacy-level availability. DEA quota figures are quoted verbatim from the Federal Register orders (expressed in grams of anhydrous acid or base). The October 2025 percentage is calculated from the two quota figures DEA published. CDC figures are from the published MMWR report. The shortage-duration figure is the mean for all resolved amphetamine-derivative shortages in the cited 2001–2023 analysis (not amphetamine salts alone). Availability status is reported as of the cited source dates and changes frequently; consult the live FDA Drug Shortages database for the current picture.

1. U.S. Food and Drug Administration. “FDA Announces Shortage of Adderall” (posted October 12, 2022; shortage of the immediate-release formulation of amphetamine mixed salts). https://www.fda.gov/drugs/drug-safety-communications/fda-announces-shortage-adderall
2. U.S. Food and Drug Administration. FDA Drug Shortages database (search by active ingredient, e.g. “amphetamine”). https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
3. U.S. Drug Enforcement Administration. “Adjustment to the Aggregate Production Quota for d-Amphetamine (For Sale) and Methylphenidate (For Sale) for 2025” (final order; effective October 2, 2025; FR Doc. 2025-19335). Federal Register. https://www.federalregister.gov/documents/2025/10/02/2025-19335/
4. U.S. Drug Enforcement Administration. “Established Aggregate Production Quotas for Schedule I and II Controlled Substances… for 2026” (final order, January 5, 2026; FR Doc. 2025-24277). Federal Register Vol. 91, No. 2 / govinfo.gov. https://www.govinfo.gov/content/pkg/FR-2026-01-05/html/2025-24277.htm
5. Centers for Disease Control and Prevention. Staley BS, et al. “Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults — National Center for Health Statistics Rapid Surveys System, United States, October–November 2023.” MMWR Morb Mortal Wkly Rep 2024;73(40):890–895. https://www.cdc.gov/mmwr/volumes/73/wr/mm7340a1.htm
6. Journal of Pediatric Pharmacology and Therapeutics (2025). Analysis of amphetamine-derivative drug shortages reported to the University of Utah Drug Information Service, January 1, 2001 – December 31, 2023. https://pmc.ncbi.nlm.nih.gov/articles/PMC12288551/

Frequently Asked Questions

Is there still an Adderall shortage in 2026?

Yes. As of early 2026 the FDA's shortage notice from October 2022 remains live, and ASHP lists both immediate-release and extended-release amphetamine mixed salts in active shortage. Availability is improving unevenly following DEA quota increases, and varies considerably by strength, region, and pharmacy [1][2][3].

When will the Adderall shortage end?

No official end date exists. The DEA raised production quotas by 25% in October 2025 and set higher 2026 quotas in January 2026, but quota increases take months to translate into pharmacy stock. Independent estimates generally point to consistent supply returning in late 2026 or 2027 [8][9][14].

What can I do if my pharmacy is out of Adderall?

Contact your prescriber promptly: prescriptions for Schedule II medications generally can't be transferred between pharmacies, so a new prescription needs to be sent to a pharmacy that has stock. Call pharmacies first to confirm availability, try independent pharmacies, and ask your prescriber about alternative strengths or formulations that are in stock [2][4].

What are doctors prescribing when Adderall is hard to find?

Depending on the individual, prescribers may consider a different strength of the same medication, another stimulant such as lisdexamfetamine or methylphenidate where available, or non-stimulant options such as atomoxetine, viloxazine, or guanfacine ER, which are not subject to DEA production quotas. Which option fits is a clinical decision made case by case [2][11].

How do I check which ADHD medications are in shortage?

Search the FDA Drug Shortage Database by active ingredient rather than brand name (for example, "amphetamine" rather than "Adderall"). The ASHP drug shortage pages add manufacturer-by-manufacturer detail, including estimated release dates for specific strengths [2][3].

How can I support my focus day to day while supply is unreliable?

Anchor the basics first: a regular sleep window, daily movement, external structure like timers and written lists, and steady meals. On the nutrition side, a plant-powered food supplement such as Brainzyme® FOCUS PRO™ can support normal mental performance and help reduce tiredness as part of a daily routine. Medication decisions themselves should always sit with your prescriber.

---

Further Reading

For live status, the FDA Drug Shortage Database and the ASHP shortage listings are the two sources worth bookmarking. For background on how stimulant and non-stimulant options compare and where supplements genuinely fit, see our guides to study drugs and their risks and what the research says about natural focus support.

Sources and References

1. U.S. Food and Drug Administration. FDA Announces Shortage of Adderall (October 2022, notice still active). Source
2. American Society of Health-System Pharmacists. Drug Shortage Detail: Amphetamine Mixed Salts, Immediate-Release Tablets (id 857) and Extended-Release Capsules (id 863). Source
3. U.S. Food and Drug Administration. Drug Shortages / FDA Drug Shortage Database. Source
4. PBS NewsHour (2023). A "perfect storm" led to an ADHD medication shortage. Here's why. Source
5. Danielson, M.L., et al. (2023). Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults — United States, 2016–2021. MMWR, 72(13). Source
6. Centers for Disease Control and Prevention (2024). ADHD Diagnosis, Treatment, and Telehealth Use in Adults. MMWR, 73(40). Source
7. Drug Enforcement Administration (2025). Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances for 2026. Federal Register, November 28, 2025. Source
8. Drug Enforcement Administration (2025). Adjustment to the Aggregate Production Quota for d-Amphetamine and Methylphenidate for 2025. Federal Register, October 2, 2025. Source
9. Drug Enforcement Administration (2026). Established Aggregate Production Quotas for Schedule I and II Controlled Substances for 2026. Federal Register, January 5, 2026. Source
10. Drug Enforcement Administration (2026). DEA Releases 2026 Aggregate Production Quotas (press release, January 9, 2026). Source
11. MEDvidi (2026). ADHD Medication Shortage List (January 2026 update). Source
12. Centers for Disease Control and Prevention (2024). Health Advisory HAN-00510: Disrupted Access to Prescription Stimulant Medications (June 13, 2024). Source
13. Journal of Pediatric Pharmacology and Therapeutics (2025). Analysis of amphetamine salts shortage events, 2001–2023. Source
14. ISSUP / Zohar, B. (2026). Is Adderall Still in Shortage in 2026? (March 2026 status review). Source

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional about your medication, diagnosis, or any individual health concern. Never start, stop, or change a prescription medication without your prescriber's guidance.